Evaluation of Artificial Lighting Sources for the Acquisition of Color Infrared Imagery Under Glasshouse Conditions

English: Research was conducted to evaluate the spectral properties, illumination intensities and lighting patterns of four basic categories of bulbs and lamps which could conceivably serve as sole lighting sources for the acquisition of color infrared (CIR) imagery under glasshouse conditions. Bulbs and lamps in two major categories (fluorescent tubes and sodium- and mercury-vapor glasshouse lamps) were deemed unsuitable for this purpose either because they emitted little or no nearinfrared (NIR) radiation or because they imparted an overall bluish cast that seriously degraded the quality of CIR imagery. All of the incandescent and quartz halogen lamps evaluated in these studies exhibited spectral properties suitable for CIR image acquisition, i.e., they emitted relatively high levels of both visible and NIR radiation. However, most bulbs and lamps in these categories were characterized by either inadequate levels of illumination or reflectors that produced a circular lighting pattern in which luminosity varied substantially from the center portion of the image to the edges. The most suitable bulb evaluated was a heavy-duty (500W) quartz halogen lamp with a rectangular reflector which, when modified by the addition of crumpled aluminum foil to the reflector housing, produced adequate levels of illumination that was distributed in a near-uniform pattern across the target area. Color infrared imagery of plant foliage acquired using this lamp as a sole lighting source was comparable in quality to imagery of the same plant material acquired under natural lighting conditions. The performance of this particular lamp is used to exemplify the stringent requirements of any lamp under consideration as a sole lighting source for CIR image acquisition within the glasshouse environment. Spanish: Se investigaron las propiedades espectrales, las intensidades de iluminación y los patrones de luz de cuatro tipos básicos de bulbos y lámparas que podrían servir como fuentes únicas de luz para la adquisición de imágenes infrarrojas (CIR) bajo condiciones de invernadero. No se consideraron adecuados para este propósito los bulbos y las lámparas en dos categorías importantes (tubos de fluorescencia y lámparas de invernadero de vapor de mercurio y sodio ya que o emitieron muy poca o ninguna radiación infrarroja cercana (NIR) o porque impartieron un tono azul que degradó seriamente la calidad de las imágenes CIR. Todas las lámparas incandescentes y de halógeno de cuarzo evaluadas en estos estudios exhibieron propiedades espectrales adecuadas para la adquisición de imágenes infrarrojas, por ejemplo, emitieron niveles relativamente altos de radiación visible y de radiación cercana al infrarrojo. Sin embargo, las mayoría de los bulbos y lámparas en esta categoría se caracterizaron por producir niveles inadecuados de iluminación o por producir un patrón de luz circular en el cual la luminosidad varió substancialmente de la porción central de la imagen a las orillas. El bulbo probado que resultó mas adecuado fue la lámpara de halógeno-cuarzo con un reflector rectangular el cual, cuando se modificó por la adición de papel aluminio arrugado al nicho del reflector, produjo niveles adecuados de iluminación que se distribuyeron en un patrón casi uniforme a lo largo de la área expuesta. Las imágenes infrarrojas del follaje vegetal tomadas usando esta lámpara como única fuente de luz fueron comparables en calidad a las imágenes del mismo follaje tomadas bajo condiciones de luz natural. El desempeño de esta lámpara en particular es usado para ejemplificar los estrictos requerimientos para cualquier lámpara que sea usada como única fuente de luz para la adquisición de imágenes de color infrarrojo en ambiente de invernadero

Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.

Prostate cancer is a highly heritable disease with large disparities in incidence rates across ancestry populations. We conducted a multiancestry meta-analysis of prostate cancer genome-wide association studies (107,247 cases and 127,006 controls) and identified 86 new genetic risk variants independently associated with prostate cancer risk, bringing the total to 269 known risk variants. The top genetic risk score (GRS) decile was associated with odds ratios that ranged from 5.06 (95% confidence interval (CI), 4.84-5.29) for men of European ancestry to 3.74 (95% CI, 3.36-4.17) for men of African ancestry. Men of African ancestry were estimated to have a mean GRS that was 2.18-times higher (95% CI, 2.14-2.22), and men of East Asian ancestry 0.73-times lower (95% CI, 0.71-0.76), than men of European ancestry. These findings support the role of germline variation contributing to population differences in prostate cancer risk, with the GRS offering an approach for personalized risk prediction

Germline variation at 8q24 and prostate cancer risk in men of European ancestry

Chromosome 8q24 is a susceptibility locus for multiple cancers, including prostate cancer. Here we combine genetic data across the 8q24 susceptibility region from 71,535 prostate cancer cases and 52,935 controls of European ancestry to define the overall contribution of germline variation at 8q24 to prostate cancer risk. We identify 12 independent risk signals for prostate cancer (p < 4.28 × 10−15), including three risk variants that have yet to be reported. From a polygenic risk score (PRS) model, derived to assess the cumulative effect of risk variants at 8q24, men in the top 1% of the PRS have a 4-fold (95%CI = 3.62–4.40) greater risk compared to the population average. These 12 variants account for ~25% of what can be currently explained of the familial risk of prostate cancer by known genetic risk factors. These findings highlight the overwhelming contribution of germline variation at 8q24 on prostate cancer risk which has implications for population risk stratification

Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants

Prostate cancer is a polygenic disease with a large heritable component. A number of common, low-penetrance prostate cancer risk loci have been identified through GWAS. Here we apply the Bayesian multivariate variable selection algorithm JAM to fine-map 84 prostate cancer susceptibility loci, using summary data from a large European ancestry meta-analysis. We observe evidence for multiple independent signals at 12 regions and 99 risk signals overall. Only 15 original GWAS tag SNPs remain among the catalogue of candidate variants identified; the remainder are replaced by more likely candidates. Biological annotation of our credible set of variants indicates significant enrichment within promoter and enhancer elements, and transcription factor-binding sites, including AR, ERG and FOXA1. In 40 regions at least one variant is colocalised with an eQTL in prostate cancer tissue. The refined set of candidate variants substantially increase the proportion of familial relative risk explained by these known susceptibility regions, which highlights the importance of fine-mapping studies and has implications for clinical risk profiling. © 2018 The Author(s).Prostate cancer is a polygenic disease with a large heritable component. A number of common, low-penetrance prostate cancer risk loci have been identified through GWAS. Here we apply the Bayesian multivariate variable selection algorithm JAM to fine-map 84 prostate cancer susceptibility loci, using summary data from a large European ancestry meta-analysis. We observe evidence for multiple independent signals at 12 regions and 99 risk signals overall. Only 15 original GWAS tag SNPs remain among the catalogue of candidate variants identified; the remainder are replaced by more likely candidates. Biological annotation of our credible set of variants indicates significant enrichment within promoter and enhancer elements, and transcription factor-binding sites, including AR, ERG and FOXA1. In 40 regions at least one variant is colocalised with an eQTL in prostate cancer tissue. The refined set of candidate variants substantially increase the proportion of familial relative risk explained by these known susceptibility regions, which highlights the importance of fine-mapping studies and has implications for clinical risk profiling. © 2018 The Author(s).Peer reviewe

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

OBJECTIVE: To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension. METHODS: Patients who completed the REGAIN randomized controlled trial and continued into the open-label extension were included in this tertiary endpoint analysis. Patients were assessed for the MGFA post-intervention status of improved, unchanged, worse, MM, and pharmacologic remission at defined time points during REGAIN and through week 130 of the open-label study. RESULTS: A total of 117 patients completed REGAIN and continued into the open-label study (eculizumab/eculizumab: 56; placebo/eculizumab: 61). At week 26 of REGAIN, more eculizumab-treated patients than placebo-treated patients achieved a status of improved (60.7% vs 41.7%) or MM (25.0% vs 13.3%; common OR: 2.3; 95% CI: 1.1-4.5). After 130 weeks of eculizumab treatment, 88.0% of patients achieved improved status and 57.3% of patients achieved MM status. The safety profile of eculizumab was consistent with its known profile and no new safety signals were detected. CONCLUSION: Eculizumab led to rapid and sustained achievement of MM in patients with AChR+ refractory gMG. These findings support the use of eculizumab in this previously difficult-to-treat patient population. CLINICALTRIALSGOV IDENTIFIER: REGAIN, NCT01997229; REGAIN open-label extension, NCT02301624. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with AChR+ refractory gMG achieved MM, compared with 13.3% who received placebo

Minimal Symptom Expression' in Patients With Acetylcholine Receptor Antibody-Positive Refractory Generalized Myasthenia Gravis Treated With Eculizumab

The efficacy and tolerability of eculizumab were assessed in REGAIN, a 26-week, phase 3, randomized, double-blind, placebo-controlled study in anti-acetylcholine receptor antibody-positive (AChR+) refractory generalized myasthenia gravis (gMG), and its open-label extension

Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.

Prostate cancer is a polygenic disease with a large heritable component. A number of common, low-penetrance prostate cancer risk loci have been identified through GWAS. Here we apply the Bayesian multivariate variable selection algorithm JAM to fine-map 84 prostate cancer susceptibility loci, using summary data from a large European ancestry meta-analysis. We observe evidence for multiple independent signals at 12 regions and 99 risk signals overall. Only 15 original GWAS tag SNPs remain among the catalogue of candidate variants identified; the remainder are replaced by more likely candidates. Biological annotation of our credible set of variants indicates significant enrichment within promoter and enhancer elements, and transcription factor-binding sites, including AR, ERG and FOXA1. In 40 regions at least one variant is colocalised with an eQTL in prostate cancer tissue. The refined set of candidate variants substantially increase the proportion of familial relative risk explained by these known susceptibility regions, which highlights the importance of fine-mapping studies and has implications for clinical risk profiling